Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 5.9% – Should You Buy?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares shot up 5.9% during mid-day trading on Tuesday . The stock traded as high as $20.71 and last traded at $20.19. 88,365 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 388,220 shares. The stock had previously closed at $19.07.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ARCT shares. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $66.75.

Arcturus Therapeutics Trading Up 8.9 %

The firm has a market capitalization of $562.33 million, a price-to-earnings ratio of -9.35 and a beta of 2.63. The business’s fifty day moving average price is $17.56 and its 200 day moving average price is $20.26.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period in the prior year, the company earned ($0.61) earnings per share. As a group, sell-side analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 15.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARCT. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 846 shares during the period. nVerses Capital LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares during the last quarter. Nordea Investment Management AB raised its holdings in Arcturus Therapeutics by 3.7% in the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after acquiring an additional 2,335 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Arcturus Therapeutics by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.